PharmaVentures
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors.
Our key offerings include:
Transactions / deal negotiations;
Product / technology valuations;
Deal term advice;
Due diligence & expert reports;
Strategy formulation;
Alliance management; and
Expert opinion for litigation/arbitration cases.
PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.
Bionomics Limited
Bionomics Limited is a productive drug discovery and development engine room focused on new treatments for cancer and serious disorders of the central nervous system . Through application of its proprietary technology platforms, MultiCore, Angene and ionX. Bionomics Limited has generated multiple drug candidates and targets in the therapeutics areas of cancer, anxiety, multiple sclerosis and epilepsy. The company has a strong out-license record in conjunction with its in-house development program which has seen two highly promising drugs enter clinical trials in the past two years.
Background
Bionomics was founded in 1999 by a group of Australia's leading healthcare researchers and initially established technology platforms in the genomics of epilepsy, angiogenesis and breast cancer.
Using its CNS technologies, Bionomics became the first company in the world to develop a genetic test for Severe Myoclonic Epilepsy of Infants, a "catastrophic" form of epilepsy for which standard treatments are inappropriate.
Using its Angene cancer target discovery platform, Bionomics has identified over 150 human genes implicated in angiogenesis - the growth in blood vessels that feed tumors.
In 2005, the company achieved significant milestones in applying its technology to drug discovery. Through the acquisition of two companies, Neurofit Preclinical Research and Iliad Chemicals, it became the first company in Australia to establish a fully integrated small molecule drug discovery platform. The company now has proprietary technologies for each step in the drug discovery process: Target Discovery and Validation, Compound Libraries, High Throughput Screening, Medicinal Chemistry and Preclinical Development.
The company has internal small molecule discovery programs operating in the following four areas: Angiogenesis and Vascular Targeting Agents (cancer); anxiety/ epilepsy and multiple sclerosis (CNS diseases).
Bionomics has commercial partnerships with a number of leading healthcare companies including Merck Serono, GenMab, Athena Diagnostics, LabCorp, Perkin Elmer, and Genetic Technologies Ltd.